Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Tim Cruise who wrote (4001)	5/5/1998 6:31:00 PM
From: Michael Burry	Respond to of 78516

My opinion on ENMD: IMO, what they are saying their drug does is the only realistic shot at a cancer cure. Halting mitosis, immunologic targeting - these have had a run. But for the last several years doctors have known that the key to killing cancer (and curing diabetic retinopathy and other diseases) is cutting off its food supply - the new blood vessels that are requisite for tumor growth. Angiotensin is the first drug to show possibilities on this front, and it is exciting indeed. But, doctors have known about this for quite a while. Entremed has had its run due to the speculative fervor in the market place. Did you see the other unrelated "cancer" companies rally today? Pure stupiditiy. Entremed is no Bre-X or Centennial. It is a bonafide ethical biotech, with two potential blockbusters. But a better bet is to wait for a market correction and buy BMY at cheaper levels, IMO. Mike